Could NAMPT inhibition become a potential treatment option in hepatocellular carcinoma?

Expert Rev Anticancer Ther. 2017 Apr;17(4):289-291. doi: 10.1080/14737140.2017.1298447. Epub 2017 Mar 8.

Authors

Antje Garten^{1

2}, Susanne Schuster^{3

2}, Melanie Penke²

Affiliations

¹ a Institute of Metabolism and Systems Research, College of Medical and Dental Sciences , University of Birmingham , Birmingham , UK.
² c Center for Pediatric Research, Hospital for Children and Adolescents , Leipzig University , Leipzig , Germany.
³ b Department of Pediatrics , University of California San Diego , La Jolla , CA , USA.

PMID: 28271737
DOI: 10.1080/14737140.2017.1298447

No abstract available

Keywords: APO866; CHS-828; FK866; GMX1778; Hepatocarcinoma; NAD; Sorafenib; nicotinamide phosphoribosyltransferase; resistance; sirtuin.

Publication types

Editorial

MeSH terms

Animals
Antineoplastic Agents / pharmacology
Carcinoma, Hepatocellular / drug therapy*
Carcinoma, Hepatocellular / enzymology
Cytokines / antagonists & inhibitors*
Drug Design
Humans
Liver Neoplasms / drug therapy*
Liver Neoplasms / enzymology
Nicotinamide Phosphoribosyltransferase / antagonists & inhibitors*

Substances

Antineoplastic Agents
Cytokines
Nicotinamide Phosphoribosyltransferase
nicotinamide phosphoribosyltransferase, human